Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is Prior authorization Entresto Aetna?
Entresto combines sacubitril (a neprilysin inhibitor) and valsartan (an angiotensin receptor blocker) to reduce heart strain by enhancing the body’s natural cardiovascular protective mechanisms. The FDA approved Entresto for reducing cardiovascular death and hospitalization for heart failure in adults and for treating symptomatic heart failure in pediatric patients age 1 and older. It is one of the most commonly prescribed heart failure medications in cardiology practice.
Quick Answer: Getting Aetna Prior Authorization for Entresto
Quick answer: To get prior authorization for Entresto (sacubitril/valsartan) with Aetna, submit a PA request documenting a heart failure diagnosis (ICD-10 I50.x) with LVEF at or below 40% (HFrEF) or above 40% (HFpEF), prior trial or intolerance of an ACE inhibitor or ARB, a 36-hour washout if transitioning from an ACEI, and recent labs (BNP or NT-proBNP, eGFR, potassium). Aetna typically requires an NYHA class II-IV designation plus a signed medical necessity letter. Standard decisions arrive within 7 calendar days under CMS-0057-F (urgent within 72 hours).
Aetna's Specific PA Criteria for Entresto
Aetna operates multiple plan types, and each has different Entresto PA requirements. Submitting a PA without checking the specific plan type first causes avoidable denials.
Commercial plans: Entresto typically sits on Tier 3 or Tier 4 with mandatory step therapy. The patient must have tried and failed, or be documented as intolerant to, an ACE inhibitor or ARB. Required documentation includes echocardiogram with LVEF value (must be within the last 12 months), NYHA functional class assessment, heart failure diagnosis with specific ICD-10 codes (I50.20, I50.22, I50.32, or I50.42), and prior ACE/ARB records showing drug name, dose, duration, and reason for discontinuation. The prescriber must be a cardiologist or demonstrate that a cardiology consultation informed the prescribing decision.
Medicare Advantage: Pre-certification is required for all Aetna MA plans. Some plans have shifted to preferring generic sacubitril/valsartan since mid-2025, with brand Entresto requiring a formulary exception request. Under CMS-0057-F, standard decisions must come within 7 calendar days and urgent decisions within 72 hours. Check the specific MA plan’s formulary before assuming brand vs. generic requirements.
Aetna Better Health (Medicaid): This Medicaid managed care product uses a completely separate formulary from Aetna’s commercial and MA plans. PA typically requires confirmed HFrEF with documented LVEF, prior ACE/ARB trial, and in some states, quantity limits apply. NJ Aetna Better Health enforces quantity limits that may not match the prescribing schedule. Verify supply duration matches.
Common checklist for all Aetna plan types: 1. Echocardiogram with LVEF value documented (within 12 months) 2. NYHA functional class assessment (Class II, III, or IV) 3. Heart failure ICD-10 codes: I50.20, I50.22, I50.32, I50.42 4. Prior ACE inhibitor or ARB trial records with specific drug names, doses, start/end dates, and outcome 5. Step therapy exception documentation if the patient cannot tolerate ACE/ARB 6. Prescriber NPI and cardiology credentials or consultation documentation
Step-by-Step Entresto PA Process with Aetna
Step 1: Verify eligibility and formulary. Confirm coverage, check brand vs. generic formulary status, identify tier and step therapy requirements.
Step 2: Gather clinical documentation. Echo with LVEF, NYHA class, HF diagnosis, prior ACE/ARB records, prescriber credentials, LOMN for HFmrEF cases (LVEF 41-49%).
Step 3: Submit. Use Aetna portal, CoverMyMeds, or designated electronic method. Attach all documentation with initial request.
Step 4: Track. Aetna must respond within 7 days standard, 72 hours urgent (CMS-0057-F). Check portal daily. Respond to info requests within 24 hours.
Step 5: Document outcome. Record approval number, authorized dates, quantity, restrictions. Set reauthorization reminder 30 days before expiration.
For commercial patients with cost barriers: Together with ENTRESTO copay program may reduce cost to $10 per fill.
Save 40-70% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
Common Entresto Denial Reasons with Aetna
Understanding the specific denial patterns for Entresto with Aetna allows your team to prevent them rather than react to them.
Step therapy not met. This is the most common Entresto denial. Aetna requires documentation that the patient tried an ACE inhibitor or ARB before Entresto. The documentation must include the specific drug name, dose, duration of therapy, and the specific reason for discontinuation. Stating “patient intolerant” without clinical details is insufficient. Include the adverse event (angioedema, persistent cough, hyperkalemia), the date it occurred, and any treatment adjustments attempted before discontinuation.
Incomplete documentation. Missing echocardiogram results, undocumented LVEF value, or absent NYHA functional class assessment triggers denial. These are required elements, not optional. Attach everything from the checklist on the first submission. Sending a partial submission and planning to “send the rest later” adds 5-10 business days and invites denial.
LVEF above threshold. Most Aetna criteria require LVEF at or below 40% (HFrEF). For patients with HFmrEF (LVEF 41-49%), the standard criteria may not apply, but clinical guidelines support Entresto use. Submit a letter of medical necessity citing the ACC/AHA 2022 Class IIb recommendation for HFmrEF. Request peer-to-peer review immediately if denied, as this is a clinical judgment call best resolved physician-to-physician.
Generic preferred, brand denied. Since mid-2025, many Aetna plans have shifted to preferring generic sacubitril/valsartan. A brand Entresto request on these plans will be denied unless the prescriber submits a formulary exception with documentation explaining why brand is medically necessary. For most patients, switching to generic is appropriate. If brand is required due to formulation tolerance issues or other clinical reasons, prepare the exception documentation before submitting.
Non-formulary exclusion. Some employer groups exclude Entresto from their benefit entirely. This is different from a formulary preference. No PA will succeed for a plan that excludes the drug. Confirm formulary status during eligibility verification before prescribing. If excluded, submit a formulary exception with complete medical necessity documentation.
How to Appeal an Entresto PA Denial from Aetna
The appeal success data for Entresto denials strongly favors filing. Over 80% of initial Medicare Advantage PA denials are overturned on appeal when proper documentation is provided. The problem is not appeal success rates. It is that most practices never file the appeal.
Internal appeal (Level 1): File within the payer’s deadline window, typically 60-180 days from the denial date. Include the original PA submission plus additional evidence that directly addresses the specific denial reason. Under CMS-0057-F, Aetna must provide specific clinical reasons for the denial, so your appeal can respond to each stated reason with targeted documentation. If the denial was for step therapy, include the missing drug trial records. If the denial was for LVEF threshold, include the letter of medical necessity with guideline citations.
Peer-to-peer review: This is the fastest path to overturn for Entresto denials because the clinical case for Entresto in heart failure is strong and well-supported by trial data. Prepare the cardiologist with a concise summary of the denial reason, the patient’s current LVEF, NYHA class, medication history, and the PARADIGM-HF, PARAGON-HF, or EMPEROR-Preserved trial data supporting the specific indication. A 10-minute P2P call can resolve in days what a written appeal takes weeks to accomplish.
External review (Level 2): If the internal appeal is denied, request an independent external review through the state insurance department. In New York, file through DFS (Department of Financial Services). In New Jersey, file through DOBI (Department of Banking and Insurance). In California, file through DMHC (Department of Managed Health Care). External review decisions are typically binding on the payer.
Expedited appeal: For patients with decompensated heart failure, acute exacerbation, or hospitalization, Aetna must respond to expedited appeal requests within 72 hours under CMS-0057-F. Document the clinical urgency clearly when requesting expedited review.
Entresto Medicaid Coverage: New York, New Jersey, and California
New York: MCOs (Healthfirst, Fidelis, MetroPlus, Molina) have separate formularies. 2026 Empire Plan lists sacubitril-valsartan as preferred. Aetna Better Health NY has its own Medicaid formulary. PA requires HFrEF, LVEF, prior ACE/ARB trial.
New Jersey: Medicaid PDL (February 2026) covers sacubitril-valsartan with quantity limit. Aetna Better Health NJ formulary at aetnabetterhealth.com/newjersey. Verify supply duration matches prescribing schedule.
California: Medi-Cal Rx covers generic. Brand Entresto removed from Medi-Cal formulary May 1, 2026, requiring TAR. Medi-Cal MCOs (L.A. Care, Health Net, Molina, Blue Shield CA Promise) maintain own formularies. Transition patients to generic before May 2026.
Generic Sacubitril/Valsartan and How It Changes the Entresto PA Process
FDA approved first generics in 2024. Multiple manufacturers launched mid-2025 across all three dosage strengths. Brand: $675/month. Generic: $32-$63/month with discount programs.
Aetna is shifting generic to preferred tiers starting January 2026. This means: generic may need less documentation, brand may require formulary exception, patients on brand may face mandatory switch, and PA requirements may differ on the same plan.
Actions: Check whether the plan prefers generic, prepare formulary exception for brand if needed, consider starting new prescriptions on generic, use Novartis copay program only for brand-specific patients.
Why Cardiology Practices Outsource Entresto Prior Authorization
Heart failure drug PA requires LVEF review, step therapy exception workflows, payer-specific criteria, and tight timelines. A single submission takes 20-35 minutes. Denied cases add 1-2 hours for appeals. U.S. PA coordinator costs $45,000-$60,000/year (over $75,000 fully loaded).
Staffingly’s PA specialists work at $399/week (volume discounts to $299/week) with 48-72 hour onboarding. 70% cost savings. Our cardiology prior authorization team handles Entresto PAs across Aetna commercial, MA, and Medicaid. Step therapy exceptions, denial follow-up, appeals, formulary exceptions, reauthorization tracking, and payer portal submissions across 50+ EHR systems.
99.2% clean claim rate. SOC 2 Type II, HITRUST, ISO 27001, HIPAA. 800+ providers. 4.9 rating.
Cardiology practices running Entresto PA in-house typically find that the workflow splits unpredictably across a front-desk coordinator, a medical assistant, and the prescribing physician for peer-to-peer calls. That fragmentation produces the denial patterns described above. A dedicated PA team, whether internal or outsourced, concentrates payer rule knowledge, maintains a library of Aetna-specific LOMN templates, and tracks reauthorization deadlines so that no patient lapses between approval periods. The result is a measurable reduction in treatment abandonment for the exact patient population where abandonment carries the highest clinical risk: heart failure patients whose condition deteriorates without guideline-directed therapy.
Staffingly’s Entresto workflow also includes proactive tracking of the generic sacubitril/valsartan formulary shift across all Aetna product lines. When a plan moves generic to preferred tier mid-year, every pending Entresto PA in the queue needs to be re-evaluated for formulary exception submission. Missing that shift creates a cascade of denials that the practice only catches at the pharmacy level, after the patient has already been inconvenienced.
What Did We Learn?
- Aetna requires PA across all plan types with different criteria per plan
- Step therapy is the most common denial trigger. Document prior ACE/ARB trial in initial submission
- LVEF thresholds may not match ACC/AHA guidelines for HFmrEF. Use LOMN and peer-to-peer
- Generic availability is shifting formulary dynamics. Check plan preferences
- State Medicaid rules differ across NY, NJ, and CA
- CMS-0057-F: 7-day standard, 72-hour urgent timelines. Public reporting begins March 2026
- Over 80% of MA PA denials are overturned on appeal
- Outsourcing at $399/week (volume discounts to $299/week) saves 70% vs. in-house staffing
Q1: What documentation does Aetna require for Entresto PA? Echo with LVEF (within 12 months), NYHA functional class, ICD-10 HF diagnosis, prior ACE/ARB trial records with dates and outcomes, prescriber NPI and cardiology credentials. For step therapy exceptions, include specific adverse reaction with dates and severity.
Q2: How long does Entresto PA take with Aetna? Under CMS-0057-F, 7 calendar days standard, 72 hours urgent. Complete submissions typically process in 3-7 business days. Incomplete submissions extend to 2-3 weeks. With appeal, total can reach 4-8 weeks.
Q3: What if Aetna denies Entresto PA? Review the specific denial reason (required under CMS-0057-F). Submit additional evidence addressing that reason. Request peer-to-peer review for fastest resolution. Over 80% of MA denials are overturned on appeal.
Q4: Does Aetna cover generic sacubitril/valsartan? Yes. Many plans now prefer generic ($32-$63/month vs. $675 brand). Switching may reduce or remove the PA requirement. If brand is necessary, submit a formulary exception.
Q5: How much does it cost to outsource Entresto PA? Staffingly starts at $399/week (volume discounts to $299/week) vs. $45,000-$60,000/year in-house. 70% savings. Handles all Aetna plan types including step therapy exceptions, denials, appeals, and reauthorization. 99.2% clean claim rate. 800+ providers. 48-72 hour onboarding. A 15-Day Risk-Free Pilot is available so your cardiology practice can evaluate approval rates and turnaround times against your current baseline before making any long-term commitment.
Ready to Cut Prior Authorization and Eligibility Headaches?
Staffingly helps practices like yours get paid faster with a 99.2% clean-claim rate, 65-70% cost savings, and 48-72 hour go-live. SOC 2 Type II, HITRUST, and ISO 27001 certified. HIPAA compliant.
